Literature DB >> 34185138

Can the BMI-based dose regimen be used to reduce injection activity and to obtain a constant image quality in oncological patients by 18F-FDG total-body PET/CT imaging?

Jie Xiao1,2,3, Haojun Yu1,2,3, Xiuli Sui1,2,3, Yan Hu1,2,3, Yanyan Cao1,2,3, Guobing Liu1,2,3, Yiqiu Zhang1,2,3,4, Pengcheng Hu1,2,3, Ying Wang5, Chenwei Li5, Baixuan Xu6, Hongcheng Shi7,8,9,10.   

Abstract

PURPOSE: PET image quality is influenced by the patient size according to the current guideline. The study aimed to propose an optimized dose regimen to yield a constant image quality independent of patient habitus to meet the clinical needs.
METHODS: A first patient cohort of 78 consecutive oncological patients (59.7 ± 13.7 years) who underwent a total-body PET/CT scan were retrospectively enrolled to develop the regimen. The patients were randomly distributed in four body mass index (BMI) groups according to the World Health Organization (WHO) criteria. The liver SNR (signal-to-noise ratio, SNRL) was obtained by manually drawing regions of interest (ROIs) and normalized (SNRnorm) by the product of injected activity and acquisition time. Fits of SNRnorm against different patient-dependent parameters were performed to determine the best correlating parameter and fit method. A qualitative assessment on image quality was performed using a 5-point Likert scale to determine the acceptable threshold of SNRL. Thus, an optimized regimen was proposed and validated by a second patient cohort consisted of prospectively enrolled 38 oncological patients.
RESULTS: The linear fit showed SNRnorm had the strongest correlation (R2 = 0.69) with the BMI than other patient-dependent parameters and fit method. The qualitative assessment indicated a SNRL value of 14.0 as an acceptable threshold to achieve sufficient image quality. The optimized dose regimen was determined as a quadratic relation with BMI: injected activity (MBq) = 39.2 (MBq)/(- 0.03*BMI + 1.49)2. In the validation study, the SNRL no longer decreased with the increase of BMI. There was no significant difference of the image quality regarding the value of SNRL between different BMI groups (p > 0.05). In addition, the injected activity was reduced by 75.6 ± 2.9%, 72.1 ± 4.0%, 67.1 ± 4.4%, and 64.8 ± 3.5% compared with the first cohort for the four BMI groups, respectively.
CONCLUSION: The study proposed a quadratic relation between the 18F-FDG injected activity and the patient's BMI for total-body 18F-FDG PET imaging. In this regimen, the image quality can maintain in a constant level independent of patient habitus and meet the clinical requirement with a reduced injected activity.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Dose optimization; FDG; Image quality; PET/CT imaging; Patient habitus; Total-body PET

Mesh:

Substances:

Year:  2021        PMID: 34185138     DOI: 10.1007/s00259-021-05462-5

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  17 in total

1.  FDG PET in response evaluation of bulky masses in paediatric Hodgkin's lymphoma (HL) patients enrolled in the Italian AIEOP-LH2004 trial.

Authors:  Egesta Lopci; Maurizio Mascarin; Arnoldo Piccardo; Angelo Castello; Caterina Elia; Luca Guerra; Eugenio Borsatti; Alessandra Sala; Alessandra Todesco; Pietro Zucchetta; Piero Farruggia; Angelina Cistaro; Salvatore Buffardi; Patrizia Bertolini; Maurizio Bianchi; Maria Luisa Moleti; Feisal Bunkheila; Paolo Indolfi; Franca Fagioli; Alberto Garaventa; Roberta Burnelli
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-09-15       Impact factor: 9.236

2.  Integrating manual diagnosis into radiomics for reducing the false positive rate of 18F-FDG PET/CT diagnosis in patients with suspected lung cancer.

Authors:  Fei Kang; Wei Mu; Jie Gong; Shengjun Wang; Guoquan Li; Guiyu Li; Wei Qin; Jie Tian; Jing Wang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-07-18       Impact factor: 9.236

3.  The image quality, lesion detectability, and acquisition time of 18F-FDG total-body PET/CT in oncological patients.

Authors:  Yi-Qiu Zhang; Peng-Cheng Hu; Run-Ze Wu; Yu-Shen Gu; Shu-Guang Chen; Hao-Jun Yu; Xiang-Qing Wang; Jun Song; Hong-Cheng Shi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-05-18       Impact factor: 9.236

4.  Development and validation of an 18F-FDG PET radiomic model for prognosis prediction in patients with nasal-type extranodal natural killer/T cell lymphoma.

Authors:  Hongxi Wang; Shengnan Zhao; Li Li; Rong Tian
Journal:  Eur Radiol       Date:  2020-05-20       Impact factor: 5.315

Review 5.  Total-Body PET: Maximizing Sensitivity to Create New Opportunities for Clinical Research and Patient Care.

Authors:  Simon R Cherry; Terry Jones; Joel S Karp; Jinyi Qi; William W Moses; Ramsey D Badawi
Journal:  J Nucl Med       Date:  2017-09-21       Impact factor: 10.057

6.  Optimum lean body formulation for correction of standardized uptake value in PET imaging.

Authors:  Abdel K Tahari; David Chien; Javad R Azadi; Richard L Wahl
Journal:  J Nucl Med       Date:  2014-06-24       Impact factor: 10.057

7.  Total-body PET/CT using half-dose FDG and compared with conventional PET/CT using full-dose FDG in lung cancer.

Authors:  Hui Tan; Xiuli Sui; Hongyan Yin; Haojun Yu; Yusen Gu; Shuguang Chen; Pengcheng Hu; Wujian Mao; Hongcheng Shi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-11-27       Impact factor: 9.236

8.  FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0.

Authors:  Ronald Boellaard; Roberto Delgado-Bolton; Wim J G Oyen; Francesco Giammarile; Klaus Tatsch; Wolfgang Eschner; Fred J Verzijlbergen; Sally F Barrington; Lucy C Pike; Wolfgang A Weber; Sigrid Stroobants; Dominique Delbeke; Kevin J Donohoe; Scott Holbrook; Michael M Graham; Giorgio Testanera; Otto S Hoekstra; Josee Zijlstra; Eric Visser; Corneline J Hoekstra; Jan Pruim; Antoon Willemsen; Bertjan Arends; Jörg Kotzerke; Andreas Bockisch; Thomas Beyer; Arturo Chiti; Bernd J Krause
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-12-02       Impact factor: 9.236

9.  Diagnostic accuracy of positron emission tomography/computed tomography-driven biopsy for the diagnosis of lymphoma.

Authors:  Alessandro Broccoli; Cristina Nanni; Alberta Cappelli; Francesco Bacci; Alessandro Gasbarrini; Elena Tabacchi; Carlo Piovani; Lisa Argnani; Riccardo Ghermandi; Elena Sabattini; Rita Golfieri; Stefano Fanti; Pier Luigi Zinzani
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-06-15       Impact factor: 9.236

10.  Staging FDG PET-CT changes management in patients with gastric adenocarcinoma who are eligible for radical treatment.

Authors:  Karen D Bosch; Sugama Chicklore; Gary J Cook; Andrew R Davies; Mark Kelly; James A Gossage; Cara R Baker
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-08-03       Impact factor: 9.236

View more
  4 in total

1.  The feasibility of ultralow-activity 18F-FDG dynamic PET imaging in lung adenocarcinoma patients through total-body PET/CT scanner.

Authors:  Jing Lv; Hongyan Yin; Haojun Yu; Guobing Liu; Hongcheng Shi
Journal:  Ann Nucl Med       Date:  2022-07-20       Impact factor: 2.258

2.  Relating18F-FDG image signal-to-noise ratio to time-of-flight noise-equivalent count rate in total-body PET using the uEXPLORER scanner.

Authors:  Edwin K Leung; Yasser G Abdelhafez; Eric Berg; Zhaoheng Xie; Xuezhu Zhang; Reimund Bayerlein; Benjamin Spencer; Elizabeth Li; Negar Omidvari; Aaron Selfridge; Simon R Cherry; Jinyi Qi; Ramsey D Badawi
Journal:  Phys Med Biol       Date:  2022-06-10       Impact factor: 4.174

3.  Exploration of the total-body PET/CT reconstruction protocol with ultra-low 18F-FDG activity over a wide range of patient body mass indices.

Authors:  Xiuli Sui; Hui Tan; Haojun Yu; Jie Xiao; Chi Qi; Yanyan Cao; Shuguang Chen; Yiqiu Zhang; Pengcheng Hu; Hongcheng Shi
Journal:  EJNMMI Phys       Date:  2022-03-03

4.  The predictive value of total-body PET/CT in non-small cell lung cancer for the PD-L1 high expression.

Authors:  Bingxin Hu; Huibin Jin; Xiali Li; Xinyu Wu; Junling Xu; Yongju Gao
Journal:  Front Oncol       Date:  2022-09-23       Impact factor: 5.738

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.